SCHEMBL30190844

SCHEMBL30190844

C=CC(=O)Nc1cccc(-c2ccc3nc(N)nc(N)c3c2)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 5/20 0.51
▸ JAK3 P52333 3/20 0.51
▸ BTK Q06187 6/20 0.49
▸ ITK Q08881 2/20 0.49
▸ JAK1 P23458 1/20 0.48
▸ MAP2K7 O14733 1/20 0.48
▸ AURKA O14965 1/20 0.48
▸ DHFR P00374 1/20 0.48
▸ TDP2 O95551 1/20 0.47
▸ FYN P06241 1/20 0.47
▸ SRC P12931 1/20 0.47
▸ VCP P55072 1/20 0.47
▸ MTOR P42345 1/20 0.47
▸ BLK P51451 1/20 0.47
▸ BMX P51813 1/20 0.47
▸ PIK3CD O00329 2/20 0.47
▸ PLCG1 P19174 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24150188 1.00 MAP4K4 (0.51) MAP4K4JAK3BTKITKJAK1
SCHEMBL24150553 0.91 DHFR (0.60) MAP4K4JAK3BTKITKJAK1
SCHEMBL30190678 0.91 DHFR (0.60) MAP4K4JAK3BTKITKJAK1
SCHEMBL30191072 0.88 MAP4K4 (0.48) MAP4K4JAK3BTKITKJAK1
SCHEMBL24150909 0.88 MAP4K4 (0.48) MAP4K4JAK3BTKITKJAK1
SCHEMBL24150527 0.84 MAP4K4 (0.73) MAP4K4FYNSRCVCPPIK3CD
SCHEMBL30190523 0.80 JAK3 (0.58) JAK3BTKITKJAK1MAP2K7
SCHEMBL24151662 0.80 JAK3 (0.58) JAK3BTKITKJAK1MAP2K7
SCHEMBL24150187 0.79 PLCG1 (0.56) MAP4K4JAK3BTKITKJAK1
SCHEMBL30190386 0.79 PLCG1 (0.56) MAP4K4JAK3BTKITKJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11926632-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2024-03-12 — — US disclosed
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS MAP4K4 1652/4885JAK3 4427/4885BTK 4194/4885
US-11926632-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS MAP4K4 1652/4885JAK3 4427/4885BTK 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback